Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
Completed · Phase 2 · Has a placebo group
Conditions studied: Unresectable Melanoma, Metastatic Melanoma
In brief
The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma
Key facts
- Study ID
- NCT01927419
- Run by
- Bristol-Myers Squibb
- People needed
- 142
- Starts
- 2013-08-23
- Expected to finish
- 2021-02-26
- Last updated by the study team
- 2022-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- San Francisco Oncology Associates — San Francisco, California, United States
- Orlando Health Inc — Orlando, Florida, United States
- University Of Louisville Medical Center, Inc., Dba — Louisville, Kentucky, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Washington University School Of Medicine — St Louis, Missouri, United States
- Comprehensive Cancer Centers Of Nevada — Las Vegas, Nevada, United States
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
- University Of New Mexico Cancer Center — Albuquerque, New Mexico, United States
- NYU Clinical Cancer Center — New York, New York, United States
- Memorial Sloan Kettering Nassau — New York, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- The Christ Hospital — Cincinnati, Ohio, United States
- Oregon Health & Science University — Portland, Oregon, United States
- St. Luke's Hospital — Easton, Pennsylvania, United States
- GHS Cancer Institute — Greenville, South Carolina, United States
- Huntsman Cancer Institute — Salt Lake City, Utah, United States
- University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr — Madison, Wisconsin, United States
- Hopital Larrey — Toulouse, France
- Institut Gustave Roussy — Villejuif, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.